Differentiation induction is an effective therapy for acute promyelocytic leukemia (APL), which dramatically responds to all-trans-retinoic acid (ATRA). Recent studies have indicated that combinatorial use of retinoid and nonretinoid compounds, such as histone deacetylase inhibitors, arsenics, and PKA agonists, has higher therapeutic value in this disease and potentially in other malignancies. In a screen of 370 compounds, we identified benzodithiophene analogues as potent enhancers of ATRA-induced APL cell differentiation. These effects were not associated with changes in global histone acetylation and, for the most potent compounds, were exerted at very low nanomolar concentrations, and were paralleled by enhancement of some, but not all, ATRAmodulated gene expressions. Investigating the mechanism underlying the effects of these drugs on ATRA-induced APL cell differentiation, we have shown that benzodithiophenes enhance ATRA-mediated dissociation and association of corepressor N-CoR and coactivator p300 acetyltransferase, respectively, with retinoic acid receptor (RAR) A proteins. These data suggest that benzodithiophenes act at the level of receptor activation, possibly by affecting posttranslational modification of the receptor (and/or coregulators), thus leading to an enhancement in ATRA-mediated effects on gene expression and APL cell differentiation. Given the specificities of these low benzodithiophene concentrations for PML-RARA and RARA, these drugs may be useful for combinatorial differentiation therapy of APL and possibly other acute myelogenous leukemia subtypes in which the overall ATRA signaling is suppressed. (Cancer Res 2005; 65(17): 7856-65) 
Introduction
Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21) translocation, which results in the fusion of retinoic acid receptor a gene (RARa) on chromosome 17 to the promyelocytic leukemia (PML) gene on chromosome 15 (see ref. 1 for review and references therein). The resulting fusion oncoprotein PML-RARa has been shown to play a central role in the pathogenesis of APL (2) (3) (4) . It disrupts the normal structure of the PML nuclear body (5), interferes with cell growth regulatory functions of PML (6) , and blocks the RARa pathway regulating myelomonocytic differentiation (7) .
The retinoid X receptor (RXR)/RAR heterodimers normally bind to retinoic acid response elements (RARE) in the absence of ligands, repressing transcription by recruiting nuclear receptor corepressor complexes that contain histone deacetylases (HDAC; see ref. 8 for review and references therein). All-trans-retinoic acid (ATRA) at physiologic concentrations triggers the dissociation of corepressors and the association of coactivators with histone acetyltransferase activities, such as CREB binding protein or p300 (8) . This process leads to activation of ATRA-responsive genes via alteration of chromatin structure and enables cellular differentiation of normal myelomonocytic progenitor cells. In APL cells, PMLRARa/RXR tetramers (9) , which bind to RAREs and a variety of other nuclear receptor hormone response elements (9, 10) , interact with corepressors more strongly than RARa/RXR heterodimers, and only at pharmacologic doses ATRA can trigger the corepressor/coactivator exchange, leading to activation of gene transcription and differentiation of leukemic blasts (see refs. 11-13 for reviews and references therein).
Important therapeutic implications of these findings are that agents capable of inhibiting enzymatic components of the corepressor complexes, such as HDAC inhibitors, could stimulate the effects of ATRA on gene expression and enhance the differentiation of leukemic cells. Indeed, a number of studies have shown enhancement of ATRA response by various HDAC inhibitors on APL cells both in vitro (14, 15) and in vivo (16) and some effects were also observed using such drug combination on non-APL acute myelogenous leukemia (AML) cells in vitro (17) (18) (19) . Nevertheless, other agents, such as hexamethylene bisacetamide and DMSO, which do not possess HDAC inhibitory activities, can also potentiate ATRA responses in APL (20) . The mechanisms by which these effects are mediated are not understood.
We have used NB4 cells with reduced ATRA sensitivity to screen for additional drugs, which synergize with ATRA to induce APL cell differentiation and which may prove to be more clinically useful than currently known HDAC inhibitors or HMBA. Among 370 different compounds screened, benzodithiophenes were identified as agents that potently stimulated ATRA effects on leukemic cell differentiation. 6 Benzodithiophene analogues were previously shown to have potent antineoplastic activities in a number of cancer cell lines, including HL-60 acute myeloid leukemia cells (21) (22) (23) . When biological effects of benzodithiophenes in selected cell lines were evaluated using COMPARE computations against National Cancer Institute (NCI) screening data from test compounds, they did not correlate with any mechanisms defined in the NCI ''Standard Agent'' data base (23) .
We have now discovered that at nanomolar concentrations, benzodithiophene analogues, which alone have no obvious biological activities at these low levels, can effectively potentiate induction of APL cell differentiation with suboptimal concentrations of ATRA, although proapoptotic effects of benzodithiophenes are seen only at micromolar concentration. 6 The underlying mechanism for the effects of benzodithiophenes on ATRA-mediated differentiation seems to involve enhancement in the rate of exchange of corepressors for coactivators with RARa proteins.
Materials and Methods
Cell lines and reagents. Human monocytic cell line U-937 and human kidney cell line 293T were obtained from American Type Culture Collection (Manassas, VA). Human APL cell line NB4 was a gift of M. Lanotte (Hôpital St. Louis, Paris, France). Cells were grown in RPMI 1640 (Life Technologies Ltd., Paisley, United Kingdom) containing 100 units/mL penicillin, 100 Ag/mL streptomycin, 20 mmol/L glutamine, and 10% fetal bovine serum, in a humidified atmosphere of 95% air and 5% CO 2 at 37jC. ATRA was purchased from Sigma-Aldrich Company Ltd. (Dorset, United Kingdom). Benzodithiophenes were obtained from NCI.
Reverse transcription and real-time PCR reagents were purchased from Life Technologies and Eurogentec, Inc. (Seraing, Belgium), respectively. Antiacetyl-histone H4 antiserum was purchased from Upstate Ltd. (Lake Placid, NY) and horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin G (IgG) was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Luciferase and h-galactosidase assays and calcium phosphate transfection reagents were purchased from Promega Ltd. (Madison, WI).
Nitroblue tetrazolium assay. Cell suspension (1 Â 10 6 cells/mL, 1 mL) in HBSS (Invitrogen Ltd., Paisley, United Kingdom) was mixed with an equal volume of HBSS containing 1 mg/mL nitroblue tetrazolium (NBT; Sigma) and 0.4 Ag/mL phorbol 12-myristate 13-acetate (Sigma), and incubated at 37jC for 30 minutes. After centrifugation at 12,000 Â g for 1 minute, the supernatant was discarded and formazan deposits were dissolved in 0.1 mL of DMSO. Absorption of the formazan solution was measured at 580 nm.
Transient transfections. Electroporation was done using a Bio-Rad Gene Pulser II at 800 AF and 270 V. Approximately 20 Â 10 6 U-937 cells were transfected with 18 Ag of pREP4-(RARE) 3 -tk-luc and with 2 Ag of pCMV-h-galactosidase as an internal control. Cells were rested for 3 hours after transfection, and then incubated with or without ATRA and indicated benzodithiophene compounds for 16 hours. Luciferase and h-galactosidase assays were done following commercial protocols (Promega). Transfection of 293T cells was carried out using the calcium phosphate precipitation method. 293T cells were plated in a 24-well plate at 0.5 Â 10 5 to 1.0 Â 10 5 cells/well (not exceeding 60% confluence). Cells were transfected with 200 ng of pREP4-(RARE) 3 -tk-luc, 50 ng of pPSG5-RARa1 or pPSG5-PML-RARa, and 100 ng of pCMV-hgalactosidase as an internal control. Sufficient DNA carrier was added to normalize the total amount of DNA to 0.5 Ag. Luciferase activity was determined after 16 hours. Mammalian two-hybrid assays were done in U-937 cells using 8 Ag of pGAL4-(UAS) 5 -tk-Luc, 2.2 Ag of pGAL4(DBD)-NCoR or pGAL4(DBD)-p300, 7.8 Ag of pVP16-RARa, and 2 Ag of pCMV-h-galactosidase as an internal control, with electroporation conditions described above. All plasmids listed above have been previously described (15, 24) .
Reverse transcription. Total RNA was extracted from cells using RNABee kit (Biogenesis Ltd., Poole, United Kingdom). Reverse transcription was done at the following conditions: RNA and random hexamers were denatured for 5 minutes at 65jC; after transferring the reaction tube to ice, M-MLV reverse transcriptase, deoxynucleotide triphosphates, RNase inhibitor, DTT, and reverse transcription buffer were added and incubated for 10 minutes at 25jC and 50 minutes at 37jC (see ref. 25 for detail).
Real-time PCR. Primers and probes were designed using Primer Express software (Perkin-Elmer, Foster City, CA); the sequences are presented in Table 1 . Primers and probes for RARa2 and PBGD transcripts were synthesized by Applied Biosystems (Boston, MA); primers for other genes were synthesized by Invitrogen. Labeled probes were used for detection of RARa2 and PBGD mRNA levels, whereas SYBR Green was used to quantify other mRNA levels. All the real-time PCR reagents were from Eurogentec. PCR reactions were done at the following conditions: 2 minutes at 50jC, 10 minutes at 95jC, then 50 cycles at 95jC for 15 seconds and 65jC for 1 minute in the ABI Prism 7700 Sequence Detector System (ABI, Foster City, CA). DNA array analysis. NB4 cells were incubated with ATRA, NSC682994, or ATRA plus NSC682994 for indicated time points, and total RNA was extracted from cells using RNABee kit (Biogenesis Ltd., Poole, United Kingdom). Microarray experiment was done at the Genome Centre, Whitehead Institute/Massachusetts Institute of Technology, using Affymetrix human genome U133 chip A, containing 22,283 genes and expressed sequence tags. Data analysis was done using component plane presentation integrated selforganizing map, built in the Matlab environment (26) . Lysates were centrifuged (15,000 Â g, 20 minutes, 4jC). Two-fold concentrated SDS sample buffer [217 mmol/L Tris-HCl (pH 6.7), 17.4% glycerol, 5% SDS, 9% 2-mercaptoethanol, 0.002% bromophenol blue] was added to cell lysate, boiled for 5 minutes, and electrophoresed on a 12% SDS-polyacrylamide gel at 20 mA for 2 hours. Rainbow protein molecular weight standards (Amersham, Little Chalfont, United Kingdom) were run concurrently. Proteins electrophoretically were transferred to nitrocellulose membranes (35 mA, 1 hour). Membranes were blocked for 1 hour at room temperature with 5% milk protein, 0.1% Tween 20 in PBS (PBS-Tween), rinsed twice, followed by three 10-minute washes with PBS-Tween. Membranes were probed at room temperature with rabbit anti-acetylhistone H4 antiserum at 1:2,000 dilution in PBS-Tween with 3% milk protein for 1 hour. After washing, membranes were probed with HRPconjugated goat anti-rabbit IgG at 1:5,000 dilution in PBS-Tween with 3% milk protein for 1 hour. After washing, blots were developed with the Enhanced chemiluminescence detection system (Amersham). 
Results
To investigate the possible mechanisms underlying the effects of benzodithiophene analogues on APL cell differentiation, we evaluated the effects of different benzodithiophene derivatives (Fig. 1) 
, and NSC682994 (4,8-dibutanoyl-benzo[1,2-b:4,5-bV]dithiophene)-on PML-RARa activity. After cotransfecting a luciferase reporter containing three copies of RARE with a PML-RARa expression vector in 293T cells, we found that benzodithiophene derivatives 1 to 3 (see Fig. 1 for chemical structures) effectively potentiated induction of PML-RARa with suboptimal concentration of ATRA (0.5 Amol/L), although these benzodithiophenes alone have no effect on the reporter activity (Fig. 2) . Among these three benzodithiophenes, NSC656240, in which acidic group of NSC656243 at C-2 in the third ring was replaced with a hydroxy, and NSC682994 with an open quinone structure and no C-2 substitution, NSC682994 was the most potent.
NSC656240 and NSC682994 stimulated ATRA activation of PMLRARa at 50 and 25 nmol/L, respectively, in contrast to NSC656243, which required micromolar concentrations (Fig. 2) . The effects on PML-RARa were consistent with the results of cell differentiation assays where NSC682994 also displayed the most potent activity (23) . It is worth noting that although NSC682994 was the most powerful differentiation inducer, higher concentrations of this compound than for the other benzodithiophenes were required to induce apoptosis (data not shown), suggesting that opening the quinone structure might have resulted in some loss of cytotoxic activity of NSC682994. Thus, it may be possible to separate the quinone cytotoxic effects from differentiation effects, which require benzodithiophene moieties, by further structural alterations. Differences in potencies among these compounds (1-3) in stimulating ATRAinduced gene expression and differentiation may be due to the potential differences in their membrane solubility. Because compounds NSC656240 and NSC682994 were more potent, they were chosen for further analysis. To show whether the same effects of benzodithiophenes on PML-RARa activation by ATRA can be observed in APL cells, we transfected an APL cell line (NB4) with the luciferase reporter containing three copies of RARE and measured its activity after treatment with NSC656240 or NSC682994, with or without ATRA (Fig. 3A) . Using NBT reduction assay, we also evaluated the effects of such combinatorial treatments on NB4 cell differentiation. Results of both assays were in agreement with the data derived from transfection experiments with 293T cells. Benzodithiophenes enhanced induction of both reporter activity and NB4 cell differentiation by ATRA (Fig. 3A and B) . Previously, we have shown that expression of ATRA-inducible RARa2 isoform increases with myelomonocytic differentiation of normal hematopoietic progenitors as well acute myeloid leukemia cells (24, 27) . Consistent with these earlier data, we find that enhancement of ATRA differentiation of APL cells by benzodithiophene correlates with enhancement of the RARa2 mRNA levels (Fig. 3C and D) . The enhanced induction of RARa expression by benzodithiophene was time dependent and was more evident after 72 hours of treatment ( Fig. 3C and D) . These effects of benzodithiophenes on ATRA-induced gene expression and APL cell line differentiation were very similar to those observed with HDAC inhibitors such as sodium butyrate (Figs. 2 and 3) . The most potent benzodithiophenes enhanced the levels of differentiation, reporter activity, and expression from an endogenous ATRA-responsive promoter, such as that of RARa2, to similar levels as sodium butyrate but at 100-fold lower concentrations. The levels of RARa2 increased with time and at 72 hours were equivalent to those obtained with ATRA and sodium butyrate treatment (Fig. 3D) . To evaluate whether other primary ATRA-response genes are similarly coactivated by NSC682994, we also examined mRNA levels for RIG-I and TGM-2 genes, which contain RAREs in their promoters and are induced by ATRA during leukemic cell differentiation. As expected, both RIG-I (28) and TGM-2 (29) were induced by ATRA and, similarly to RARa2, the levels of their expression were potentiated by NSC682994 (Fig. 4A and B) .
To further detail transcriptional changes synergistically induced by ATRA and NSC682994, high-density microarrays were done on the NB4 cells treated with NSC682994, ATRA, or ATRA plus NSC682994 at 8, 24, and 48 hour time points using Affymetrix Genechip. After a data normalization procedure, a total of 5,884 genes revealed reliable expression values across all the nine samples. Based on these numerical values, self-organizing map, an artificial intelligent algorithm, was applied to cluster coregulated genes using 400 hexagonal prototype vectors on a two-dimensional lattice (20 Â 20 grids). To detail transcriptional changes of each sample at the global scale, the self-organizing map outputs were visualized by component plane presentations (26) . As shown in Fig. 5 , each presentation illustrates a sample-specific global transcriptional map in which all up-regulated, moderately regulated, and down-regulated genes are well delineated, permitting direct determination of functional significances of genes clustered to each map unit with respect to each sample. By comparing regulatory patterns in identical positions between presentations, it is clearly shown that NSC682994 alone has a limited impact on the modulation of gene expression throughout the time course (NSC 8, 24, and 48 hours). In the combined treatments, however, NSC682994 significantly potentiates the ATRA-mediated gene regulation, as shown by modulatory statues of genes mapped to top right and bottom left corner/edge areas of the map (NSC and ATRA 48 hours of Fig. 5 ). Among the 1,179 modulated genes of which expression varied at least 2-fold compared with untreated sample in at least one of the nine samples, 302 genes were synergistically modulated. Most of these genes were modulated at 24 and 48 hours. Table 2 lists examples of genes regulated by ATRA, which were (groups B and D) and were not (groups A and C) potentiated by benzodithiophene. Expression profiles of selected genes in groups B and D were then confirmed using real-time PCR. Using RNA isolated from a different experiment, real-time PCR analysis generated data highly similar to that derived from the microarray ( for example, see Fig. 6A and B) for interleukin 8 (IL-8; expression potentiated by benzodithiophene) and MYC (expression further down-regulated by benzodithiopohene).
Given the similarity in RARa2 induction profile of ATRA and sodium butyrate to ATRA plus NSC682994, we asked whether benzodithiophenes could constitute a novel class of HDAC inhibitors, and therefore we examined whether they affect the overall state of histone acetylation. In contrast to sodium butyrate, none of the benzodithiophenes change the overall levels of acetylation of histone H4 (Fig. 7) . Although we cannot exclude the possibility that benzodithiophenes can affect histone acetylation in a limited way that could not be detected by analysis of total acetylated histone H4 levels, these results suggest that these compounds exert their effects on ATRA-dependent gene expression and transcriptional activation of RARs by a different mechanism.
To evaluate whether the effects of benzodithiophenes on ATRA-mediated activation of gene expression could be due to enhancement of corepressor disassociation and recruitment of coactivator, we carried out a mammalian two-hybrid assay using RARa fused with the VP16 activation domain (RARa-VP16) and either N-CoR or p300 fused to the DNA binding domain of GAL4 [GAL4(DBD)-NCoR or GAL4(DBD)-p300]. After cotransfection of luciferase reporter containing thymidine kinase basal promoter and five GAL4 binding sites with expression vectors for RARa-VP16 and either GAL4(DBD)-N-CoR or GAL4(DBD)-p300 into U-937 cells, the relative luciferase activity was determined. The decrease of luciferase activity in the case of RARa and N-CoR due to ATRA treatment indicates the dissociation of RARa-VP16 and GAL4(DBD)-N-CoR proteins (Fig. 8A) , whereas increase in luciferase activity with ATRA treatment when RARa-VP16 and GAL4(DBD)-p300 were coexpressed indicated the association between the two test proteins (Fig. 8B) . In both instances, dithiophene potentiated the ATRA effects, although NSC682994 alone had no effect on reporter activity.
Discussion
The ability of retinoids to arrest growth, induce differentiation, and cause apoptosis of a variety of malignant cell types has distinguished them as potentially important anticancer agents (30) . Nevertheless, when used therapeutically as single agents, retinoids are highly effective only in treatment of APL in which they induce differentiation of malignant cells (31) (32) (33) . This ability of APL cells to respond to ATRA with terminal differentiation is likely due to the presence of RARa gene translocation and expression of the RARa chimeric proteins, which do not respond to physiologic levels of ATRA (12, 13) . Although other differentiation inducers, such as HMBA or sodium butyrate, produce some clinical response in patients with myelodysplastic syndrome and myelogenous leukemia (34), a high-dosage requirement for these compounds renders them clinically undesirable. One possible way of enhancing the effects of retinoids on hematopoietic or other malignancies is were potentiated by NSC682994. Among these 302 genes, 163 were up-regulated and 139 were downregulated. Examples of genes up-regulated and down-regulated by ATRA alone, with NSC having no potentiating effect, are given in groups A and C; examples of genes that are up-regulated or down-regulated by ATRA with further enhancement of either effect due to addition of NSC are given in groups B and D. Bar graphs on the right were made based on the average of gene expression patterns. The numerical value shown in y axis of each diagram is logarithm of ratio with base 2 (i.e., log 2 1/1 = 0 means no change, 1 means z2-fold, and À1 means V2-fold).
to combine them with agents, which converge on a common therapeutic target (i.e., RARs). Sodium butyrate and other HDAC inhibitors, which target the enzymatic activity of unliganded RAR/ corepressor complexes, are another class of such agents (14, 15, 35) . Recently, Ikeda et al. (36) reported that triterpenoid CDDO-Im could potentiate the differentiation of NB4 APL cell line by ATRA, possibly through down-regulation of PML-RARa levels. Now we show that structurally and functionally different classes of molecules of HDAC inhibitors exert similar effects on activities of wild-type RARa as well as the PML-RARa chimeric proteins and ATRA-induced APL cell differentiation. The effects of benzodithiophenes on ATRA-mediated cell differentiation and changes in gene expression were observed at 100-fold lower concentrations than those seen with butyrates, suggesting that benzodithiophenes may be clinically more useful drugs than short fatty acids such as butyrate or valproate. Furthermore, at nanomolar concentrations, NSC682994 alone had no effects on gene transcription, suggesting a higher degree of specificity towards RAR signaling and reduced potential cellular toxicities that may be due to nonspecific effects. The results of our experiments using ATRA-responsive systems suggest that benzodithiophenes directly target the RAR and/or coregulator activities. Consistent with this, the results of two hybrid experiments addressing the effects of benzodithiophenes on ATRA-induced dissociation of corepressor and association of coactivator indicate that benzodithiophenes have specific effects on the ligand-mediated coregulator exchange that are mechanistically . Effect of benzodithiophene analogues on ATRA-modulated interactions of RARa with coactivator p300 or corepressor N-CoR. U937 cells were cotransfected with a luciferase reporter containing five GAL4 DNA binding sites, VP16-RARa, and either GAL4-NCoR (A ) or GAL4-p300 (B) expression vectors. Transfected cells were incubated with ATRA and/or NSC682994 for 16 hours, then luciferase assays were done and the relative luciferase activities (untreated cells) were determined. Similar results have been obtained in at least three independent experiments. Columns, means; bars, SD. In all cases, changes in luciferase activities were very significant (P < 0.01), with lesser significance (P < 0.05) corresponding to the result reflecting difference in effects on N-CoR dissociation (A ) between ATRA versus ''no treatment control''. Statistical analysis was done by Student's t test.
different from that of HDAC inhibitors, which target and inhibit enzymatic activity of associated HDAC. Although the mechanisms accounting for these effects are presently not clear, these effects could be due to the role of benzodithiophenes in affecting posttranslational modification of the receptor which structurally enables a higher rate of coregulator exchange. For example, phosphorylation of RARs by a number of different kinases (37) (38) (39) (40) has been shown to be both cell context dependent and to play a role in regulating their activities. Furthermore, others and we have reported observations highlighting a cross talk between ATRA and mitogen-activated protein (MAP) kinase signaling in AML cell differentiation (24, 41, 42) . Benzodithiophenes could exert effects through direct or indirect interaction with these kinase signaling pathways or an as yet unidentified pathway. Nevertheless, given that at concentrations sufficient to enhance ATRA effects benzoditiophenes do not exert significant effect on gene expression (see Results), it is unlikely that these compounds alone affect the activities of extracellular signal-regulated kinases (ERK) or other MAP kinases. In light of findings that ATRA can induce ERK2 activation in leukemic cells (42) , however, it remains to be examined whether benzodithiophenes could stimulate ATRA activation of this or other MAP kinases.
Action of benzodithiophenes on the activity of the RAR obligatory heterodimerization partner RXR is also possible, as RXR activating functions seem to be essential for many, but not all, RARdependent developmental functions (43) (44) (45) , suggesting target gene-specific activities. Such an effect would be consistent with the results of microarray experiments, which indicate that expression of some, but not all, ATRA-regulated genes is potentiated by benzodithiophenes.
Benzodithiophenes may also affect function of the nuclear receptor corepressors, rendering them less accessible to the receptors and, thus, shifting the equilibrium from repression towards activation. It has been shown that SMRT can be phosphorylated, and phosphorylation of SMRT is thought to cause loss of affinity for various transcription factors and its export into the cytoplasm (46, 47) . It is not clear, however, whether benzodithiophenes exert effects on receptor and/or coregulator phosphorylation. Effects of benzodithiophenes on translation and/or cellular localization of proteins that may affect RARa and PML-RARa function are also possible. Precise mechanisms that underlie cooperation between ATRA and benzodithiophenes in regulating gene expression and cellular differentiation remain to be established and their thorough understanding should contribute to the most effective combinatorial use of these drugs in future therapeutic application.
